Edit ID | Edit Comment | Time | |
---|
402688 | New Interpretation | 01/22/2019 1:33 PM |
Before
The interpretation was not yet created, or had been deleted.After (Current Version)
Tier 2InterpretationKDR (kinase domain receptor), also known as VEGFR2 or Flk-1, is a tyrosine kinase receptor for vascular endothelial growth factor (VEGF) and plays a key role in angiogenesis. While KDR mutations are rare, amplification or protein overexpression have been reported in small proportion of a variety of solid tumors. Genetic alteration in KDR have been identified in 10% of lung adenocarcinomas. KDR (VEGFR2) R962H lies within the protein kinase domain of the KDR. This variant has not been biochemically characterized; however, mutations in this locus have been identified in various tumor types. Most therapies blocking KDR signaling target the angiogenesis pathway in general, such as bevacizumab, an antibody that targets VEGF-A. These results should be interpreted in the clinical context.
|
Citations- Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various
- diseases. J Biochem. 2013 Jan;153(1):13-9.
- Smith NR, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res. 2010 Jul 15;16(14):3548-61.
- Comprehensive TCGA PanCanAtlas (https://gdc.cancer.gov/about-data/publications/pancanatlas).
- Zhang N, Liu H, Yue G, Zhang Y, You J, Wang H. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing. PLoS One. 2016 Apr 14;11(4):e0153546. doi: 10.1371/journal.pone.0153546. eCollection 2016. Erratum in: PLoS One. 2016 Oct 18;11(10 ):e0165251.
- Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of
- bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004May;3(5):391-400. Review.
|
Last updated: 2019-01-22 18:33:59 UTC
|